NEUROSCIENCE: Edited by Michael N. DiringerBlood pressure management in acute intracerebral hemorrhage current evidence and ongoing controversiesGioia, Laura C.a; Kate, Mahesha; Dowlatshahi, Darb; Hill, Michael D.c; Butcher, KenaAuthor Information aDivision of Neurology, University of Alberta, Edmonton, Alberta bDivision of Neurology, University of Ottawa, Ottawa, Ontario cDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Correspondence to Dr Ken Butcher, 2E3 WMC Health Sciences Centre, University of Alberta, 8440 112th St., Edmonton, Alberta T6G 2B7, Canada. Tel: +1 780 407 2171; fax: +1 780 407 1325; e-mail: firstname.lastname@example.org Current Opinion in Critical Care: April 2015 - Volume 21 - Issue 2 - p 99–106 doi: 10.1097/MCC.0000000000000182 Buy Metrics Abstract Purpose of review Spontaneous intracerebral hemorrhage (ICH) is associated with high rates of morbidity and mortality. Although treatment options are limited, a potential acute medical intervention is blood pressure (BP) reduction. The review will summarize the current evidence and remaining knowledge gaps with respect to acute BP management in acute ICH. Recent findings More than 3000 patients were enrolled in seven prospective randomized-controlled clinical trials assessing the safety and efficacy of intensive BP reduction (target <140–150 mmHg systolic) compared with current guideline-recommended BP target (<180 mmHg) in acute ICH. Overall, these trials demonstrated that intensive BP reduction is well tolerated and may be associated with a modest improvement in functional outcomes. There is still no conclusive evidence that aggressive BP reduction is associated with attenuation of hematoma growth or mortality rates. Delayed time to enrolment and difficulty in achieving intensive BP targets in a timely fashion without stringent antihypertensive protocols may partially account for the absence of proven benefit. Summary Recent trials have shown that BP lowering (<140 mmHg systolic) is well tolerated and may improve functional outcomes. Ongoing trials will provide insight into the overall benefit of early aggressive BP reduction in acute ICH. Copyright © 2015 YEAR Wolters Kluwer Health, Inc. All rights reserved.